RUIFUSHU is the first nephrology product by Simcere, and has passed the consistency evaluation. It has been recommended by numerous domestic and international guidelines as the first-line treatment for preventing rejection following organ transplantation.

In December 2019, mycophenolate mofetil was approved for the treatment of class III-IV lupus nephritis of adult patients. This indication was included in the new National Reimbursement Drug List (NRDL), updated in March.

In addition, mycophenolate mofetil can also be used to treat other autoimmune diseases such as systemic lupus erythematosus (SLE), dermatomyositis, scleroderma, IgA nephropathy, membranous nephropathy (MN) and Nephrotic syndrome (NS).